A New Biological Explanation for Sadness in Early Postpartum
TORONTO, May 4 /CNW/ - Greater levels of a brain protein called monoamine oxidase A (MAO-A) - may explain why postpartum blues and clinical depression are so common after childbirth according to an important study published today in the Archives of General Psychiatry.
Using an advanced brain imaging method, researchers at the Centre for Addiction and Mental Health discovered that levels of brain MAO-A in healthy women four to six days after delivery were 43% greater as compared to women not recently pregnant. The findings were strongest on day 5, the day when postpartum blues is usually the most severe.
MAO-A removes chemicals like serotonin that help maintain a normal mood. Greater MAO-A levels mean that this removal process is overly active making people feel sad.
"Understanding the biology of postpartum blues is important because when it is severe it leads to clinical level postpartum depression, the most common complication of childbearing affecting 13% of mothers, and one that can have a devastating impact. We hope this information may be used in the future to create dietary supplements that could provide the nutrients removed by high MAO-A and lower the risk for postpartum depression," according to Dr. Jeffrey Meyer, principal investigator for the study.
The brain imaging technique is called positron emission tomography (PET). VP of Research Dr. Bruce Pollock explains, "CAMH has the only PET centre in the world dedicated solely to mental health and addiction research. As a result we were able to apply this high level technology to better understand postpartum depression, an important research direction in mood disorders."
The study (Elevated Brain Monoamine Oxidase A Binding in the Early Postpartum Period) was funded by the Canadian Institutes of Health Research, the Ontario Mental Health Foundation, the National Alliance for Research in Depression and Schizophrenia, and the Canadian Foundation for Innovation. Dr. Meyer holds a Canada Research Chair in the Neurochemistry of Major Depression.
The Centre for Addiction and Mental Health (CAMH) is Canada's largest mental health and addiction teaching hospital, as well as one of the world's leading research centres in the area of addiction and mental health. CAMH combines clinical care, research, education, policy development, prevention and health promotion to transform the lives of people affected by mental health and addiction issues.
CAMH is fully affiliated with the University of Toronto, and is a Pan American Health Organization/World Health Organization Collaborating Centre
For further information: For more information or to request an interview, contact Michael Torres, Media Relations, CAMH at (416) 595-6015 or email [email protected]
Share this article